Targeted therapies:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Philadelphia [u.a.]
Saunders
2002
|
| Schriftenreihe: | Hematology, oncology clinics of North America
16,5 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XIII S., S. 1041 - 1313 S. Ill., graph. Darst. |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV016491459 | ||
| 003 | DE-604 | ||
| 005 | 20150204 | ||
| 007 | t | ||
| 008 | 030205s2002 ad|| |||| 00||| eng d | ||
| 035 | |a (OCoLC)51277485 | ||
| 035 | |a (DE-599)BVBBV016491459 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 |a DE-29 |a DE-355 |a DE-578 | ||
| 245 | 1 | 0 | |a Targeted therapies |c Manuel Hidalgo guest ed. |
| 264 | 1 | |a Philadelphia [u.a.] |b Saunders |c 2002 | |
| 300 | |a XIII S., S. 1041 - 1313 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Hematology, oncology clinics of North America |v 16,5 | |
| 650 | 7 | |a Moleculaire genetica |2 gtt | |
| 650 | 7 | |a Therapieën |2 gtt | |
| 650 | 7 | |a Tumoren |2 gtt | |
| 650 | 4 | |a Antineoplastic Agents |x therapeutic use | |
| 650 | 4 | |a Apoptosis |x Drug effects | |
| 650 | 4 | |a Neoplasms |x Drug therapy | |
| 650 | 4 | |a Neoplasms |x drug therapy | |
| 650 | 4 | |a Signal transduction | |
| 700 | 1 | |a Hidalgo, Manuel |e Sonstige |4 oth | |
| 830 | 0 | |a Hematology, oncology clinics of North America |v 16,5 |w (DE-604)BV000625446 |9 16,5 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=010194307&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-010194307 | ||
Datensatz im Suchindex
| _version_ | 1804129815498850304 |
|---|---|
| adam_text | lAK(.l.ll.l) IHIKAI ILS
CONTENTS
Preface xi
Manuel Hidalgo
Epithelial Growth Factor Receptor Interacting Agents 1041
Jose Baselga and Joan Albanell
The epithelial growth factor receptor (EGFR) and its ligands are
present in the majority of human tumors and are believed to play
a role in their clinical behavior. A series of preclinical studies
demonstrated that monoclonal antibodies directed at the EGFR
and inhibitors of the tyrosine kinase (TK) activity of the receptor
can suppress the growth of EGFR expressing cancer cells. For
these reasons, EGFR interacting agents moved to the clinic at the
end of the last decade. There is now clinical evidence of antitumor
activity of the TK inhibitors ZD1839 and OSI 774 against several
tumor types and of the ability of the monoclonal antibody IMC
C225 to reverse clinical chemotherapy resistance. These results are
complemented by an emerging number of compounds, mono¬
clonal antibodies, and TK inhibitors directed at the EGFR that are
in clinical development. These findings observed with different
agents and in different tumor types validate EGFR as a target for
cancer therapy. The results of ongoing studies with these agents in
diverse indications and tumor types will help to establish the role
of these therapies within our current cancer treatments.
Inhibitors of the Ras Oncogene as Therapeutic Targets 1065
Irene M. Ghobrial and Alex A. Adjei
Tumorigenesis is thought to be a result of mutations in multiple
genes that control normal cell proliferation, differentiation, and
apoptosis. Understanding the processes that govern the signaling
pathways of proliferation and the mechanisms by which mutated
genes stimulate the expression of the neoplastic phenotype can result
in novel, specific therapeutic targets. The improved understanding
of the molecular mechanisms of Ras anchorage, post translational
VOLUME 16 . NUMBER 5 • OCTOBER 2002 v
modification, and downstream effector signaling has provided an
important background for the development of Ras targeted anti
cancer therapy. These therapeutic agents include inhibitors of Ras
protein expression, such as antisense oligonucleotides and intracel¬
lular antibodies, inhibitors of Ras processing, such as farnesyl trans
ferase inhibitors and geranylgeranylase inhibitors, inhibitors of Ras
trafficking, such as heat shock protein inhibitors, and inhibitors
of Ras effector proteins, such as Raf kinase, MEK, and PI3K/Akt
kinase inhibitors.
Targeting Intracellular Signal Transduction 1089
Muralidhar Beeram and Amita Patnaik
Significant advances in the field of molecular biology over the past
decade have led to a new era in cancer therapeutics, with an explo¬
sion of rationally designed therapeutic strategies directed against
selective molecular targets. The complex array of aberrant signal
transduction proteins involved in carcinogenesis has been the focus
of target based anticancer agents. Inhibitors of intracellular signal
transduction represent a unique approach in that they inhibit criti¬
cal downstream regulatory proteins, which are vital to the process
of cellular communication. Although these agents are in early
phase evaluations, the preliminary data suggest that they are well
tolerated and capable of target inhibition in surrogate and tumor
tissue. Although the primary therapeutic benefit of these agents is
expected to be decreased tumor growth, evidence suggests that
objective tumor responses may also be achieved. There are many
unresolved questions pertaining to the development of this class of
compounds, including selection of optimal dose and schedule,
determination of relevant endpoints, methods for target validation,
and strategies for combination with cytotoxic agents. However,
despite the numerous unresolved issues, the emergence of this class
of compounds has resulted in an undeniable impact on the present
and future of cancer therapeutics.
Clinical Development of Mammalian Target of
Rapamycin Inhibitors 1101
Janet E. Dancey
Rapamycin and CCI 779 have significant in vitro and in vivo anti
proliferative activity against a broad range of human tumor cell
lines, justifying the clinical evaluation of this class of agent in can¬
cer patients. Preliminary results from phase I studies of CCI 779
suggest that the agent is well tolerated and has anti tumor activity.
The challenge to investigators is to efficiently determine what role
this class of agent will play in the treatment of cancer patients. This
article focuses on recent advances in the understanding of the
mechanisms of cell growth inhibition by rapamycin and the issues
surrounding the development of this class of agent as a potential
cancer therapy.
vi CONTENTS
Targeting the Molecular Pathophysiology of Gastrointestinal
Stromal Tumors with Imatinib 1115
George D. Demetri
The improved understanding of the molecular pathophysiology
of gastrointestinal stromal tumors (GIST), a disease that was pre¬
viously untreatable with any available systemic therapy, has led
to the development of imatinib, a well tolerated agent that can
inhibit the dysregulated KIT signaling pathways in GIST.
Imatinib represents the first (and currently the only) effective sys¬
temic therapy for patients with unresectable GIST. Imatinib ther¬
apy can induce objective responses and stabilization of disease
and can provide clinical benefit in the majority of GIST patients
treated with the drug. Other strategies are just beginning to be
explored, such as the use of imatinib earlier the in course of GIST
(eg, as adjuvant therapy after definitive surgical resection of
early stage disease). Integration of signal transduction inhibitors
into the armamentarium of cancer therapeutics will undoubtedly
continue based on this important paradigm of GIST.
Angiogenesis as a Target for Cancer Therapy 1125
Kerim Kaban and Roy S. Herbst
The necessity for tumors to create new blood vessels to grow and
the restriction of normal angiogenesis in healthy adults to only a
few short lasting situations provide very selective targets for
antiangiogenic cancer therapies. In contrast to the neoplastic cells
in their vicinity, vascular endothelial cells are genetically stable
and less likely to develop resistance to therapy. Moreover, every
cancer type is virtually a unique disease and requires tailored
therapy, but agents targeting the tumor endothelium, a relatively
uniform and normal cell type, might be effective against a broad
range of tumor types. This article reviews the biology of angio¬
genesis and some of the most common agents used to inhibit
this process.
Inhibitors of the Vascular Endothelial Growth Factor Receptor 1173
Lee S. Rosen
The continued growth of a rumor requires a series of inter related
steps that include the growth and formation of new blood vessels,
a process known as angiogenesis. As a pro angiogenic stimulus,
vascular endothelial growth factor (VEGF) has been identified as a
key component in this rather complicated cascade. Many different
studies describe the significance of VEGF as a prognostic factor or
as a means of predicting response to therapy, but we do not fully
understand how to incorporate these findings into clinical practice.
Several agents targeting VEGF have been developed and are in
various stages of human testing.
CONTENTS vii
Development of Matrix Metalloproteinase Inhibitors in
Cancer Therapy 1189
W. Thomas Purcell, Michelle A. Rudek, and Manuel Hidalgo
The matrix metalloproteinases are a family of zinc dependent pro
teinases collectively capable of degrading essentially all of the
components of the extracellular matrix. Matrix metalloproteinases
have been implicated in the process of tumor growth, invasion,
and metastasis. Based on their prominent role in cancer, matrix
metalloproteinases appear to be a relevant therapeutic target.
Over the last several years a number of new drugs with matrix
metalloproteinase inhibitory activity as the major mechanism of
action have demonstrated antitumor activity in vitro and in vivo.
Several of these agents are undergoing clinical evaluation in
patients with malignant diseases. Future directions in this field
include the development of new, more potent, specific, and less
toxic matrix metalloproteinase inhibitorss, the refinement in the
methodology of clinical trials of these agents, and the continued
combination of matrix metalloproteinase inhibitors with classic
chemotherapeutic drugs. Recent data on the capability of some
matrix metalloproteinase inhibitorss to inhibit the shedding of
extracellular domains of membrane bound receptors raise the
possibility of utilizing these compounds to enhance the activity of
receptor targeted agents.
Cyclin Dependent Kinases as New Targets for the Prevention
and Treatment of Cancer 1229
Adrian M. Senderowicz
Based on the frequent aberration in cell cycle regulatory pathways
in human cancer by cyclin dependent kinase (cdk) hyperactiva
tion, novel ATP competitive cdk inhibitors are being developed.
The first two tested in clinical trials, flavopiridol and UCN 01,
showed promising results with evidence of antitumor activity and
plasma concentrations sufficient to inhibit cdk related functions.
Best schedule to be administered, combination with standard
chemotherapeutic agents, best tumor types to be targeted, and
demonstration of cdk modulation from tumor samples from
patients in these trials are important questions that need to be
answered to advance this class of agents to the prevention and
treatment of human cancer.
Regulators of Apoptosis as Anticancer Targets 1255
Anthony W. Tolcher
Several therapeutic strategies for drug development focus on the
enhancement of tumor cell apoptosis secondary to chemotherapy,
irradiation, and hormone therapy, and improved therapeutic gain
for patients. Rationally derived molecularly targeted agents directed
to the regulation of bcl 2 family members (intrinsic pathway) are in
viii CONTENTS
late clinical studies, whereas several strategies that target the tumor
necrosis factor receptor family (extrinsic pathway of apoptosis) are in
late preclinical development. These therapeutic agents and the path¬
ways that are targeted are reviewed.
Heat Shock Protein and Proteasome Targeting Agents 1269
Chris H. Takimoto and Shrinivas Diggikar
Heat shock proteins and the ubiquitin proteasome pathway are two
different novel, new targets for cancer chemotherapy. Inhibition of
Hsp90 or the 26S proteasome can interfere with a wide range of dif¬
ferent biological processes. Despite this diversity of pharmacological
effects, new chemical entities targeting these important biological
pathways are showing promising evidence of antitumor activity.
Several of these new molecules are in clinical trials. Although these
agents are still early in clinical drug development, they highlight the
importance of targeting heat shock proteins and the ubiquitin pro¬
teasome pathway as a novel strategy for treating human cancers.
Clinical Trial Designs for Targeted Agents 1287
Brigette B.Y. Ma, Carolyn D. Britten, and Lillian L. Siu
The unique properties of contemporary targeted drugs pose major
challenges for the development of anticancer therapy, necessitating
modification of traditional clinical trial designs. This article dis¬
cusses some of the strategies employed to evaluate these agents in
the phase I to III setting, citing examples of some recently tested
targeted agents to illustrate the advantages and disadvantages of
various approaches.
Index 1307
CONTENTS ix
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV016491459 |
| ctrlnum | (OCoLC)51277485 (DE-599)BVBBV016491459 |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01427nam a2200373 cb4500</leader><controlfield tag="001">BV016491459</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20150204 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">030205s2002 ad|| |||| 00||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)51277485</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV016491459</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-578</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Targeted therapies</subfield><subfield code="c">Manuel Hidalgo guest ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia [u.a.]</subfield><subfield code="b">Saunders</subfield><subfield code="c">2002</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIII S., S. 1041 - 1313 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Hematology, oncology clinics of North America</subfield><subfield code="v">16,5</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Moleculaire genetica</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Therapieën</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Tumoren</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic Agents</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Apoptosis</subfield><subfield code="x">Drug effects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield><subfield code="x">Drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Signal transduction</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hidalgo, Manuel</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Hematology, oncology clinics of North America</subfield><subfield code="v">16,5</subfield><subfield code="w">(DE-604)BV000625446</subfield><subfield code="9">16,5</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=010194307&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-010194307</subfield></datafield></record></collection> |
| id | DE-604.BV016491459 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T19:11:08Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-010194307 |
| oclc_num | 51277485 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM DE-29 DE-355 DE-BY-UBR DE-578 |
| owner_facet | DE-19 DE-BY-UBM DE-29 DE-355 DE-BY-UBR DE-578 |
| physical | XIII S., S. 1041 - 1313 S. Ill., graph. Darst. |
| publishDate | 2002 |
| publishDateSearch | 2002 |
| publishDateSort | 2002 |
| publisher | Saunders |
| record_format | marc |
| series | Hematology, oncology clinics of North America |
| series2 | Hematology, oncology clinics of North America |
| spelling | Targeted therapies Manuel Hidalgo guest ed. Philadelphia [u.a.] Saunders 2002 XIII S., S. 1041 - 1313 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Hematology, oncology clinics of North America 16,5 Moleculaire genetica gtt Therapieën gtt Tumoren gtt Antineoplastic Agents therapeutic use Apoptosis Drug effects Neoplasms Drug therapy Neoplasms drug therapy Signal transduction Hidalgo, Manuel Sonstige oth Hematology, oncology clinics of North America 16,5 (DE-604)BV000625446 16,5 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=010194307&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Targeted therapies Hematology, oncology clinics of North America Moleculaire genetica gtt Therapieën gtt Tumoren gtt Antineoplastic Agents therapeutic use Apoptosis Drug effects Neoplasms Drug therapy Neoplasms drug therapy Signal transduction |
| title | Targeted therapies |
| title_auth | Targeted therapies |
| title_exact_search | Targeted therapies |
| title_full | Targeted therapies Manuel Hidalgo guest ed. |
| title_fullStr | Targeted therapies Manuel Hidalgo guest ed. |
| title_full_unstemmed | Targeted therapies Manuel Hidalgo guest ed. |
| title_short | Targeted therapies |
| title_sort | targeted therapies |
| topic | Moleculaire genetica gtt Therapieën gtt Tumoren gtt Antineoplastic Agents therapeutic use Apoptosis Drug effects Neoplasms Drug therapy Neoplasms drug therapy Signal transduction |
| topic_facet | Moleculaire genetica Therapieën Tumoren Antineoplastic Agents therapeutic use Apoptosis Drug effects Neoplasms Drug therapy Neoplasms drug therapy Signal transduction |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=010194307&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000625446 |
| work_keys_str_mv | AT hidalgomanuel targetedtherapies |